Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates

Manhattan ResearchManhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer® v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, “Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations – beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

1. Chantix
2. Cialis
3. Viagra
4. Aciphex
5. Ambien CR
6. Levitra
7. Lamisil
8. Lunesta
9. Wellbutrin XL
10. Ortho Evra

Source: ePharma Consumer® v7.0, Manhattan Research, LLC

To learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting www.manhattanresearch.com/ePC.htm.

Some of the additional product sites researched within ePharma Consumer® v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo-Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri-Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit www.manhattanresearch.com/ePC.htm to download the ePharma Consumer® product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

About Manhattan Research
ePharma Consumer® v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer®, Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen® Health US, Cybercitizen® Health Europe, Taking the Pulse® US, Taking the Pulse® Europe, and ePharma Physician®. Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...